IMRA Form 144 Notice — 5,250 Common Shares Planned Sale

Rhea-AI Filing Summary

Form 144 notice for proposed sale of securities. The filing reports an intended sale of 5,250 common shares through Jefferies LLC on 08/27/2025, with an aggregate market value of $106,680.00. The securities were acquired on 08/09/2022 via stock options from Enliven Therapeutics. The filer reports 59,000,000 shares outstanding. The filing also discloses four prior sales by Benjamin Hohl totaling 10,500 shares on dates in June and July 2025 with the recorded gross proceeds for each sale.

Positive

• Complete Rule 144 disclosure including broker, class, amount, acquisition date, and acquisition method
• Recent sales disclosed with dates and gross proceeds, improving transparency

Negative

• Insider executed multiple sales totaling 10,500 shares in the past three months (June–July 2025)

Insights

Securities Compliance Analyst

TL;DR: Routine Rule 144 disclosure of an officer/affiliate sale; provides required transaction and acquisition detail.

The filing supplies the standard elements required by Rule 144: identity of broker (Jefferies LLC), class, amount to be sold (5,250 shares), acquisition method (stock options on 08/09/2022), and recent sales activity by the same person (10,500 shares sold across June–July 2025). It also states the number of shares outstanding (59,000,000) and the proposed sale date (08/27/2025), which are material for resale volume calculations under Rule 144. The submission includes the signer’s representation regarding material nonpublic information.

Corporate Governance Expert

TL;DR: Disclosure is complete for a Section 144 notice; recent sales are documented but no adverse events disclosed.

The notice documents recent insider sales by an identified individual and the planned transaction through a named broker. It contains acquisition details (stock options) and demonstrates compliance with Rule 144 timing and disclosure requirements. The filing does not include any commentary on motives, internal trading plans, or additional governance actions. No material adverse information is asserted in the remarks.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Jefferies LLC 520 Madison Ave 4th Fl New York NY 10022	5250	106680.00	59000000	08/27/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/09/2022	Stock options	Enliven Therapeutics			5250	08/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Benjamin Hohl 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	06/13/2025	3000	67655.40
Benjamin Hohl 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	06/27/2025	3250	67955.75
Benjamin Hohl 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	07/10/2025	1000	22655.00
Benjamin Hohl 6200 Lookout Rd 1st FL Boulder CO 80301	Enliven Therapeutics	07/28/2025	3250	66503.61

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for IMRA report?

The filing reports a proposed sale of 5,250 common shares through Jefferies LLC on 08/27/2025 with aggregate market value $106,680.00.

Who acquired the securities being sold and how?

The securities were acquired on 08/09/2022 via stock options from Enliven Therapeutics.

How many shares outstanding does the filing state?

The filing lists 59,000,000 shares outstanding.

Were there recent sales by the same person before this filing?

Yes. Benjamin Hohl sold 3,000 shares on 06/13/2025, 3,250 on 06/27/2025, 1,000 on 07/10/2025, and 3,250 on 07/28/2025 (total 10,500 shares).

Which broker is named to execute the proposed sale?

Jefferies LLC, 520 Madison Ave, 4th Fl, New York, NY 10022, is listed as the broker.

Does the filing state any material nonpublic information?

The signer represents they do not know any material adverse information that has not been publicly disclosed.